American Gene Technologies® (AGT™) founder and CEO Jeff Galvin launched the company as a startup in 2008. Galvin had been retired from a career in Silicon Valley as a software entrepreneur and angel investor, when a 2007 meeting with acclaimed National Institutes of Health researcher Roscoe Brady, MD, PhD, showed him the power of lentivirus vectors to edit genes. That revelation drove Galvin to form AGT to pursue potential gene therapy cures for diseases like HIV, PKU and certain cancers.
On The Marc Media was integral to AGT’s marketing and PR efforts. After a successful Phase I human trial of AGT103-T (the company’s gene therapy for HIV), On The Marc Media helped AGT prepare for a corporate transformation that may result in a public company, to be called Addimmune™, which would focus on further developing the HIV gene therapy program, while AGT would work on gene therapies for other diseases.
The company needed comprehensive planning and execution of:
In particular, one of our recurring challenges involved the need to translate highly technical and scientific information into content tailored to specific audiences. AGT sought to engage with a variety of stakeholders, from HIV activists to investors to scientists to government regulators to the general public. Because gene therapy is both new to many people and controversial to some, we had to help AGT be both proactive in educating audiences as well as reactive in addressing misinformation, misconceptions and questions that arose especially in social media and online forums.
We designed and executed a sustained, comprehensive, integrated, multimedia communications strategy to achieve the companies’ goals.
On The Marc Media tailored earned-media outreach to audience-specific outlets, which each
viewed the HIV epidemic through a different lens: scientific, medical, social, policy, business, personal and more.
We pitched stories leading up to, through and following the Phase I clinical trial of AGT103-T. We spotlighted the leadership team, particularly CEO Jeff Galvin. We teased upcoming developments. And we trumpeted each success and achievement, which helped the company balance its legal
mandates with its desire to instill realistic hope in people living with HIV.
*By downloading the Insight, The Art of Tweeting you are also joining our newsletter.